Nucleic Acid Medicine Industry Trends in the Second Half of July 2026
Approval in sight for muscle diseases, while RNAi competes for clinical outcomes in cardiovascular and metabolic fields
In the second half of July 2026, the nucleic acid medicine industry saw significant progress across a wide range of areas, including regulatory review and clinical development of nucleic acid drugs for muscle diseases, late-stage clinical trials of RNAi drugs for cardiovascular and metabolic diseases, and mRNA for cancer treatment and dual-targeting siRNA.
In the first half of July, "advancement and selection in late-stage clinical trials" progressed simultaneously across diverse modalities such as ASO, siRNA, RNA editing, mRNA, and aptamers. In contrast, the second half of July was marked by news demonstrating the commercialization capabilities of nucleic acid medicines, such as approval applications, clinical outcomes in Phase 3 trials, and the continuous creation of development candidates from the same platform.
Nucleic acid medicine is entering a stage where it competes not only on the technical value of being able to control target gene expression, but also on whether it can demonstrate meaningful clinical effects for patients, obtain approval, and expand the target patient population.
Muscle-targeting nucleic acid medicine enters the approval review stage
One of the most important developments in the second half of July is the submission of a US approval application for Dyne Therapeutics' Duchenne muscular dystrophy (DMD) treatment, zeleciment rostudirsen.
This drug is a therapeutic candidate that promotes the production of functional truncated dystrophin by delivering oligonucleotides to muscle tissue for DMD patients eligible for exon 51 skipping. It utilizes Dyne's proprietary FORCE platform, combining targeted delivery to muscle tissue with exon skipping.
The US FDA has accepted the Biologics License Application (BLA) and granted it priority review. The PDUFA target action date is set for January 21, 2027, and Dyne is aiming for accelerated approval. If approved, it will be an extremely important precedent for next-generation nucleic acid medicines that combine muscle-targeting technology with exon skipping.Dyne Therapeutics announcement
Furthermore, Dyne has also received Investigational New Drug (IND) approval from the US FDA for its facioscapulohumeral muscular dystrophy (FSHD) treatment candidate, DYNE-302.
DYNE-302 is a therapeutic candidate aimed at suppressing the expression of DUX4, which is deeply involved in the pathogenesis of FSHD. A Phase 1 trial targeting ambulatory adult patients has begun, making it the company's third clinical program using the FORCE platform.Dyne Therapeutics announcement
The ability to deploy multiple clinical candidates from a single platform—DMD, myotonic dystrophy type 1, and FSHD—demonstrates not only the versatility of the delivery technology but also its value as a business foundation for continuously generating a pipeline.
Value beyond 'biomarker improvement' demonstrated by Plozasiran
In the cardiovascular and metabolic field, Arrowhead Pharmaceuticals' RNAi pipeline has made significant progress.
In the Phase 3 SHASTA-3 and SHASTA-4 trials of plozasiran for patients with severe hypertriglyceridemia (sHTG), the primary endpoint of triglyceride levels was significantly reduced compared to the placebo group. More importantly, a significant reduction in the incidence of acute pancreatitis was also demonstrated.
While the reduction in triglyceride levels is an important indicator of pharmacological action, the fact that it reduced acute pancreatitis, a serious clinical event for patients, is a result that elevates the value of plozasiran. Arrowhead aims to submit an additional approval application to the US FDA for the expansion of the indication to sHTG within the year.Arrowhead Pharmaceuticals announcement
In the development of nucleic acid medicines, there is a tendency to focus on how much target genes or blood biomarkers can be suppressed. However, in future late-stage clinical trials and market competition, product value will be determined by whether it can demonstrate outcomes directly linked to patient prognosis and medical burden, such as hospitalizations, complications, cardiovascular events, and disease progression.
Arrowhead's cardiovascular franchise expands with completion of Zodasiran Phase 3 enrollment
Arrowhead has also completed patient enrollment for the global Phase 3 YOSEMITE trial of zodasiran for homozygous familial hypercholesterolemia (HoFH).
Zodasiran is an RNAi therapeutic that suppresses the expression of ANGPTL3 in the liver. HoFH is characterized by significantly high LDL cholesterol levels and early atherosclerotic cardiovascular disease, and there are patients who are difficult to manage sufficiently even with existing treatments.
Completion of the YOSEMITE trial is scheduled for mid-2027, with a global approval application planned thereafter.Arrowhead Pharmaceuticals announcement
With plozasiran, which targets APOC3, and zodasiran, which targets ANGPTL3, advancing in parallel through late-stage development, Arrowhead is building an RNAi-based cardiovascular and metabolic disease franchise rather than just a single product. The trend of GalNAc-siRNA expanding from established technologies for rare diseases into the broader cardiovascular and metabolic disease market is finally taking concrete shape.
Competition in siRNA antithrombotic therapy targeting Factor XI intensifies
In the second half of July, there were two significant developments in siRNA therapeutics targeting Factor XI (FXI).
Argo Biopharmaceutical has administered the first dose to a participant in a Phase 1 trial of BW-41012, which is intended for the prevention of thromboembolism. BW-41012 is an siRNA targeting FXI mRNA and has also received IND approval from the National Medical Products Administration (NMPA) of China. This agent is the eighth clinical candidate for Argo, demonstrating that the company's RNAi drug discovery platform is being deployed into the clinical stage across multiple disease areas.
Meanwhile, Suzhou Ribo Life Science and Ribocure Pharmaceuticals announced positive results from a Phase 2a trial of vortosiran in patients with coronary artery disease. Good tolerability and sustained FXI activity suppression were confirmed in patients receiving standard care, marking an important clinical proof-of-concept that showed FXI suppression in patients after repeated dosing.Ribocure Pharmaceuticals announcement
With existing anticoagulant therapies, the balance between antithrombotic efficacy and bleeding risk is always a challenge. FXI is attracting attention as a promising target for next-generation antithrombotic drugs because it may be able to control thrombus formation while minimizing the impact on normal hemostatic function.
However, it remains to be confirmed in future large-scale clinical trials whether sustained suppression of FXI activity can actually reduce thrombotic events without increasing bleeding risk. The progress of BW-41012 and vortosiran indicates that the development race for antithrombotic therapy using low-frequency dosing siRNA has entered full swing.
Dual-targeting siRNA as a new option for complex metabolic diseases
South Korea's April Bio has licensed a metabolic disease therapeutic candidate based on dual-targeting siRNA from Qurient.
This candidate is designed to simultaneously suppress the expression of two genes with a single siRNA candidate, targeting metabolic diseases such as dyslipidemia. It aims to use GalNAc modification for delivery to hepatocytes and control multiple pathological pathways with a single therapeutic agent.
In chronic metabolic diseases, suppressing a single target may not always provide sufficient therapeutic efficacy. While dual-targeting siRNA involves challenges such as sequence design, off-target effects, pharmacological balance between two targets, and manufacturing control, if multiple pathways can be controlled with a single agent, it has the potential to create new product value that differs from combination therapy.
This license acquisition is also noteworthy as a move by April Bio, which has focused on antibody therapeutics, to expand its pipeline into RNA drug discovery. As GalNAc delivery becomes standardized, the focus in the future is likely to shift from 'which gene to suppress' to 'how to combine multiple targets' as a differentiator.
mRNA moves toward cancer treatment in both personalized and off-the-shelf directions
In the oncology field, Moderna announced the administration of the first dose to a subject in the United States in a Phase 1 trial of mRNA-4200 for patients with advanced or metastatic solid tumors.
mRNA-4200 is a co-development product with Immatics and encodes seven tumor antigens commonly expressed across multiple patients and cancer types. It aims to induce and amplify T-cell responses against target antigens after administration, thereby enhancing the immune response against cancer cells.Moderna announcement
Unlike personalized cancer vaccines that select antigens according to an individual patient's tumor mutations, mRNA-4200 is an off-the-shelf therapeutic candidate that combines antigens common to multiple patients.
While personalized therapy can be expected to have high precision, it requires time and cost for analysis, manufacturing, quality testing, and supply for each patient. Common antigen types involve challenges such as the accuracy of patient selection and individual differences in immune response, but they have the advantages of shorter manufacturing times, standardized supply, and a broader patient population.
In the future of the cancer mRNA field, it is thought that the industry will not converge on either personalized or off-the-shelf types, but rather move toward using both selectively depending on the cancer type, antigen properties, line of therapy, and concomitant drugs.
Clinical development of domestic mRNA vaccines in South Korea moves to Phase 2
In the infectious disease field, GC Biopharma has submitted an IND to the Ministry of Food and Drug Safety (MFDS) of South Korea for the conduct of a Phase 2 trial for its COVID-19 mRNA vaccine candidate, GC4006A.
This program is being advanced as part of a pandemic response project led by the Korea Disease Control and Prevention Agency (KDCA). Based on the results of the Phase 1 trial, the plan is to evaluate safety and immunogenicity in healthy individuals.
The COVID-19 vaccine market is shifting from a phase centered on emergency demand to one competing on sustainable business models that include rapid responses to variants, stable supply, manufacturing costs, and vaccination policies. Meanwhile, for each country, domestic development and manufacturing capabilities for mRNA vaccines also serve as a security foundation for preparing for the next pandemic.
The development of GC4006A should be viewed not just as a single COVID-19 vaccine candidate, but as the establishment of a foundation in South Korea that integrates mRNA design, manufacturing, clinical development, and regulatory compliance.
Summary of the Second Half of July: Nucleic Acid Medicine Moves from a 'Competition of Implementation' to a 'Competition of Results'
An overview of trends in the second half of July 2026 reveals that competition in the nucleic acid medicine industry is shifting to a stage where concrete results are being demanded.
First, in muscle diseases, the BLA acceptance for zeleciment rostudirsen means that targeted delivery nucleic acid medicines have entered the approval review stage. Furthermore, the entry of DYNE-302 into clinical trials demonstrates the scalability of a model that generates multiple muscle disease therapeutics from the same platform.
Second, in cardiovascular and metabolic diseases, plozasiran has shown not only improvements in lipid levels but also a reduction in acute pancreatitis, marking a stage where nucleic acid medicines are competing on clinical outcomes that are meaningful to patients. The completion of patient enrollment for the Zodasiran Phase 3 trial and the progress of FXI-targeting siRNA also confirm the trend of RNAi expanding from rare diseases to large-scale chronic disease markets.
Third, dual-targeting siRNA and shared tumor antigen-type mRNA are expanding the design philosophy of nucleic acid medicines itself. Designs that control multiple pathological pathways with a single molecule and off-the-shelf cancer therapies that can be used commonly across multiple patients are new attempts to balance clinical efficacy with business viability.
Until now, the central challenges in nucleic acid medicine have been 'can it reach the target?' and 'can it control gene expression?'. However, from now on, factors such as 'can it reduce clinical events?', 'can it lead to approval and market expansion?', and 'can it generate multiple products from a single technology?' will determine corporate value.
The second half of July can be said to have been a half-month where nucleic acid medicine began to shift from a stage of demonstrating that it is an 'implementable technology' to a stage of competing on concrete therapeutic and business results.
Information on the 'Nucleic Acid Medicine Industry Trends' Database
We organize and database information regarding domestic and international news, R&D, clinical trials, approvals/applications, partnerships, licensing, manufacturing, and intellectual property related to nucleic acid medicines into Excel, and distribute it twice a month on a paid basis.
For those who wish to subscribe, we will provide details such as included items, distribution methods, and fees. Please feel free to contact us at the email address below.
Contact:
iwao.nozawa@nra-s.com